International Angiology最新文献

{"title":"International Union of Angiology (IUA) Consensus Document on Enhanced Recovery after Surgery (ERAS) in Vascular Surgery.","authors":"Mario D'Oria, Petar Zlatanovic, Joao Rocha Neves, João Paulo-Castro, Ricardo Fernandes, Cristina Galego, Ksenija Stevanovic, Tina Novakovic, Luís Loureiro, Elena Giacomelli, Marco Campolmi, Fulvio Nisi, Enrico Giustiniano, José Oliveira-Pinto, Javier Cebrian, Daniele Mascia, Domenico Baccellieri, Nicola Troisi, Sofia Pierozzi, Giulia Bertagna, Raffaella Berchiolli, Mario Vieira, Pedro Reis, Michal Juszynski, Eduardo Silva, Joana Mourão, Joana Cruz Silva, Alessia D'Andrea, Salvatore Scali, Ranko Trailovic, Gabriele Piffaretti, Kosmas I Paraskevas, Shoaib Padaria, Jan Pitha, António Pereira-Neves, Lara R Dias, Tiago Costa-Pereira, Pier L Antignani","doi":"10.23736/S0392-9590.26.05478-7","DOIUrl":"10.23736/S0392-9590.26.05478-7","url":null,"abstract":"<p><p>Enhanced recovery after surgery (ERAS) is a multimodal perioperative care pathway designed to improve recovery, optimize patient outcomes, and enhance overall quality and satisfaction. Successful ERAS implementation requires continuous interprofessional collaboration among anesthesiologists, surgeons, nurses, nutritionists, physiatrists, and gerontologists, extending from preadmission to discharge. This consensus document, developed by the International Union of Angiology (IUA) Youth Committee and senior experts, outlines best practices for ERAS in vascular surgery. It synthesizes current evidence and expert opinions to provide a structured clinical pathway that enhances patient care and facilitates real-world application. This document has outlined key strategies to enhance perioperative outcomes in vascular surgery patients, a population at high risk for periprocedural complications, particularly cardiac events. The authors attempted to clarify and standardize key definitions and provide general guidance on broadly applying ERAS principles based on existing literature and clinical experience. While ERAS protocols for vascular surgery have been recently published by the Society for Vascular Surgery (SVS), this document offers a complementary perspective, addressing key perioperative steps and providing specific recommendations for both open and endovascular arterial procedures.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"205-238"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147873999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical treatment versus endarterectomy for symptomatic carotid stenosis: systematic review and meta-analysis. Do we need an updated randomized trial to compare carotid intervention to best medical therapy in patients with symptomatic carotid disease?","authors":"Eric T Lim, Manar Khashram","doi":"10.23736/S0392-9590.26.05553-7","DOIUrl":"10.23736/S0392-9590.26.05553-7","url":null,"abstract":"","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"239-240"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148203705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-dependent effects of rosuvastatin in deep vein thrombosis: a retrospective cohort study.","authors":"Dragan Nikolić, Janko Pasternak, Vladimir Manojlović, Slavko Budinski, Marijana Basta Nikolić, Nikola Batinić","doi":"10.23736/S0392-9590.26.05537-9","DOIUrl":"10.23736/S0392-9590.26.05537-9","url":null,"abstract":"<p><strong>Background: </strong>Deep vein thrombosis (DVT) remains associated with substantial morbidity despite anticoagulation therapy, with 20-30% experiencing recurrence and up to 50% developing post-thrombotic syndrome (PTS). Statins possess anti-inflammatory properties that may benefit DVT outcomes, but evidence for adjunctive use remains limited.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 255 patients with first-episode proximal DVT diagnosed between January 1^st, 2020 and December 31^st, 2020, with follow-up through December 31^st, 2024. Using multinomial propensity scores, we matched patients 1:1:1 who were receiving rosuvastatin 20 mg (N.=85), rosuvastatin 10 mg (N.=85), or no statin (N.=85) for ≥3 months before DVT diagnosis. All patients received guideline-directed anticoagulation. Primary outcome was composite of DVT recurrence and/or PTS. We used Cox regression for time-to-event analyses and mixed-effects models for biomarker trajectories.</p><p><strong>Results: </strong>After median follow-up of 42 months (IQR 36-48), the primary outcome occurred in 31.8% of rosuvastatin 20-mg group, 38.8% of 10-mg group, and 47.1% of controls (HR=0.67, 95% CI 0.50-0.90, P=0.008 for 20 mg vs. control). Both rosuvastatin groups showed greater reductions in inflammatory markers compared to controls. Complete vein recanalization at 48 months was observed in 74.1%, 65.9%, and 58.8% respectively (overall P=0.045; pairwise 20 mg vs. control P=0.095, Table II). Safety profiles were similar across groups, with no excess bleeding or muscle-related events.</p><p><strong>Conclusions: </strong>In this hypothesis-generating study, rosuvastatin use was associated with reduced DVT complications, with suggestions of dose-dependent effects. These associations require confirmation in prospective randomized trials before clinical recommendations can be made.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"161-173"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148251473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decision to delivery: do vascular MDT discussions achieve their intended clinical targets?","authors":"Armia N Sargious, Wisam M Taha, Muhammad A Zafar, Sohaib A Jararaa, Alaa A Al-Zaghal, Abdillahi A Roble, Laszlo Papp","doi":"10.23736/S0392-9590.26.05525-2","DOIUrl":"10.23736/S0392-9590.26.05525-2","url":null,"abstract":"<p><strong>Background: </strong>Compliance between Multidisciplinary Team (MDT) decisions and the final management plan was audited before and after the introduction of electronic documentation. This study also analyzed the underlying causes and outcomes of any discrepancies.</p><p><strong>Methods: </strong>A retrospective audit (Cycle 1) of 278 vascular MDT cases, followed by a re-audit (Cycle 2) covering 443 cases, was conducted across 24 MDT meetings between August 2021 and January 2022. Clinical management was compared with the recorded MDT decisions. Discrepancies were categorized by root cause, and associated outcomes - including mortality, limb loss, and treatment delays - were analyzed.</p><p><strong>Results: </strong>Cycle 1: 39 out of 278 MDT decisions deviated from the agreed plans (14%). The main causes were pre/intraoperative surgical plan changes (33.3%) and patient unfitness (20.5%), resulting in a 33.3% three-month mortality rate and major limb amputations. Cycle 2: Implementation improved, with 48 out of 443 decisions (10.8%) deviated from the actual plans. System delays were the leading cause (31.25%), followed by clinical reassessment changes and patient unfitness equally at (20.8%). The three-month mortality rate and amputation incidence fell to 29%.</p><p><strong>Conclusions: </strong>Electronic documentation improved MDT compliance by 3.2% and reduced amputation/ 3-month mortality outcomes by 6.9%. System delays and patient unfitness continue to hinder full adherence. The rise of discrepancies in outpatients care points to unresolved divergence issues. Further refinement of documentation and reduction of system delays are essential for improving outcomes.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"191-198"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of endovascular revascularization of upper limb thromboangiitis obliterans via palmar arch angioplasty.","authors":"Perihan Varim, Ersan Tatli, Sadık Uyanik, Malay Patel","doi":"10.23736/S0392-9590.26.05535-5","DOIUrl":"10.23736/S0392-9590.26.05535-5","url":null,"abstract":"<p><strong>Background: </strong>Thromboangiitis obliterans (TAO), or Buerger's disease, is a rare, nonatherosclerotic segmental vasculitis affecting small- and medium-sized arteries, most commonly in the extremities. Upper extremity involvement presents unique therapeutic challenges, particularly in preserving hand function and preventing amputation.</p><p><strong>Methods: </strong>We retrospectively reviewed nine male patients with angiographically confirmed upper extremity TAO. Demographics, angiographic findings, procedural details, and clinical outcomes - including revascularization success and amputation rates - were analyzed. Palmar arch angioplasty was attempted in patients with suitable anatomy and critical ischemia.</p><p><strong>Results: </strong>The mean age was 50.3±4.4 years. All patients were active smokers (mean 28.2±4.1 pack-years). Six patients (66.7%) presented with digital gangrene, while three (33.3%) had ischemic ulceration. Radial artery involvement was present in all patients, and ulnar artery involvement in 77.8%. Palmar arch angioplasty was attempted in six patients and technically successful in four (66.7%). Minor amputations occurred in eight patients (88.9%), while no major amputations were required. Patients with successful revascularization experienced improved wound healing and limb salvage.</p><p><strong>Conclusions: </strong>Endovascular revascularization, including palmar arch angioplasty, may represent a feasible limb-salvage approach in selected patients with upper extremity TAO; however, clinical outcomes remain variable, minor amputations are still frequently observed, and the technique should be interpreted as a supportive measure rather than a definitive solution.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"199-204"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147873994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of endovascular therapy in Buerger disease with critical limb ischemia: a retrospective observational study.","authors":"Orhan Rodoplu","doi":"10.23736/S0392-9590.26.05528-8","DOIUrl":"10.23736/S0392-9590.26.05528-8","url":null,"abstract":"<p><strong>Background: </strong>Buerger disease, or thromboangiitis obliterans (TAO), is a rare non-atherosclerotic vasculitis affecting distal vessels, often resulting in critical limb ischemia (CLI). Endovascular therapy (EVT) has emerged as a potential treatment, though long-term data remain limited. This study evaluates outcomes and survival predictors following EVT in patients with TAO-related CLI.</p><p><strong>Methods: </strong>A retrospective cohort of 100 patients with angiographic features consistent with thromboangiitis obliterans and critical limb ischemia was analysed, including a subgroup of patients fulfilling strict Shionoya/Olin criteria (definite TAO) and a subgroup with TAO-like angiographic patterns but coexisting atherosclerotic risk factors. Primary outcomes were technical success and limb salvage. Secondary endpoints included amputation-free survival, ulcer healing, reintervention, and vessel patency. Kaplan-Meier analysis assessed survival, with P<0.05 considered significant.</p><p><strong>Results: </strong>Mean age was 41.5±6.9 years; 51% were female, and 64% were current smokers. EVT included stenting (38%), drug-coated (31%), and plain balloon angioplasty (31%). Technical success was 92%. Limb salvage was achieved in 47%; amputation-free survival at 12 months was 51%. Kaplan-Meier analysis showed significantly longer survival in younger patients (≤40 years), never smokers, and those with ulcer healing, limb salvage, and vessel patency (all P<0.05). No significant differences were found by sex, diagnostic criteria, or reintervention.</p><p><strong>Conclusions: </strong>EVT is a viable option in TAO-related CLI, with improved outcomes linked to younger age, smoking cessation, and ulcer healing. Despite high amputation rates, targeted intervention and follow-up may improve long-term limb preservation.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"181-190"},"PeriodicalIF":1.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological thromboprophylaxis after varicose vein thermal ablation in Spain: a national survey.","authors":"Maday Cabrero Fernández, Agnieszka Nowak Tarnawska, Efrem Gómez-Jabalera, Hugo Navas, Elena Martín Morales, José L Monfort Lardies, Cristina Feijoo Cano, Luis J Álvarez Fernández","doi":"10.23736/S0392-9590.26.05489-1","DOIUrl":"10.23736/S0392-9590.26.05489-1","url":null,"abstract":"<p><strong>Background: </strong>Endovenous thermal ablation (EVTA) of varicose veins is now the first-line therapy for truncal reflux, yet consensus on peri-procedural pharmacological thromboprophylaxis is lacking.</p><p><strong>Methods: </strong>A ten-item, online, anonymized survey was distributed to all 291 members of the Spanish Chapter of Phlebology and Lymphology (CEFyL-SEACV) in February 2024. Items explored respondent demographics, anaesthesia, use, timing, drug choice and duration of pharmacological thromboprophylaxis after EVTA. Results are reported as frequencies.</p><p><strong>Results: </strong>Of 291 surgeons, 120 replied (response rate 41%, 120/291); 110 routinely performed EVTA and formed the analytic sample. Most had >10 years of venous experience (84%, 101/120) and practiced in public (48%, 58/120) or private (44%, 53/120) hospitals. Pharmacological thromboprophylaxis was prescribed by 95.5% (105/110): routinely in 80.9% (89/110) and selectively in 14.5% (16/110). Low-molecular-weight heparin (LMWH) was preferred (92.7%, 102/110); direct oral anticoagulants (DOACs) were rare (6.4%, 7/110). Prophylaxis was initiated immediately post-procedure in 39.1% (41/110), within 1-6 h in 37.1% (39/110) and ≥6 h in 22.9% (24/110). Standard duration was 6-10 days for 69.5% (73/105), whereas patients with pro-thrombotic risk factors frequently received extended courses (≥15 days in 16.2%, 17/105).</p><p><strong>Conclusions: </strong>Spanish vascular surgeons widely adopt pharmacological thromboprophylaxis after EVTA, but timing and duration vary substantially in the absence of definitive guidelines. These findings highlight the need for a national, evidence-based consensus to harmonize practice and optimize patient safety.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":"45 2","pages":"77-86"},"PeriodicalIF":1.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148029943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The associations between lower extremity peripheral arterial disease and immune-inflammatory biomarkers.","authors":"Tianbo Wang, Huan Jin","doi":"10.23736/S0392-9590.26.05490-8","DOIUrl":"10.23736/S0392-9590.26.05490-8","url":null,"abstract":"<p><strong>Background: </strong>Inflammation is recognized as a critical component in the pathogenesis of lower extremity peripheral arterial disease (PAD); however, the association between novel immune-inflammatory biomarkers - neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), Systemic Immune-Inflammation Index (SII), Systemic Inflammatory Response Index (SIRI), and Aggregate Index of Systemic Inflammation (AISI) - and PAD risk in the general population remains unexplored. This study examines the associations between PAD and NLR, PLR, MLR, SII, SIRI, and AISI.</p><p><strong>Methods: </strong>This study was a cross-sectional observational study based on the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2004. PAD was diagnosed using an Ankle-Brachial Index (ABI) ≤0.9. Finally, 6314 participants aged ≥40 years with complete information about ABI, blood cell counts, and other covariates were analyzed. Logistic regression analysis was used to examine the associations between inflammatory biomarkers and PAD. The predictive ability of inflammatory biomarkers for PAD was compared using receiver operating characteristic (ROC) curves. Subsequent mediation analysis examined the indirect effects of immune-inflammatory biomarkers on PAD via estimated glomerular filtration rate (eGFR). Finally, we performed propensity score matching (PSM) between PAD and non-PAD participants to verify the robustness of results.</p><p><strong>Results: </strong>In 6314 US adults aged ≥40 years, 548 were diagnosed with PAD. Significant associations were observed between PAD and NLR (odds ratio [OR]: 1.02; 95% confidence interval [CI]: 1.01-1.04), MLR (OR: 1.02; 95% CI: 1.00-1.04), SII (OR: 1.02; 95% CI: 1.00-1.03), SIRI (OR: 1.03; 95% CI: 1.01-1.04), and AISI (OR: 1.02; 95% CI: 1.01-1.03), according to logistic regression. PSM further validated the robustness of primary results. Mediation analysis revealed eGFR mediated portions of the relationship between PAD and NLR, MLR and SIRI (4.69%, 7.11% and 3.69% respectively). Additionally, ROC showed that SIRI exhibited a greater identification of PAD compared with other immune-inflammatory biomarkers.</p><p><strong>Conclusions: </strong>NLR, MLR, SII, SIRI, and AISI demonstrated independent associations with PAD risk, with SIRI showing a stronger association with PAD.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"124-134"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mid-term outcomes after endovascular treatment for critical limb-threatening ischemia in patients not available for vein bypass surgery.","authors":"Magdalena Broda, Egle Kavaliunaite, Stevo Duvnjak, Per Edstrøm, Hadi Riazi, Saeid Shahidi","doi":"10.23736/S0392-9590.26.05521-5","DOIUrl":"10.23736/S0392-9590.26.05521-5","url":null,"abstract":"<p><strong>Background: </strong>Evaluate mid-term outcomes, including amputations and mortality, in patients with critical limb-threatening ischemia (CLTI) deemed unsuitable for vein bypass surgery undergoing endovascular treatment in the femoropopliteal segment.</p><p><strong>Methods: </strong>A retrospective analysis was conducted including all patients undergoing endovascular treatment for CLTI at a university hospital between 2013-2017. Kaplan-Meier (KM) analyses estimated survival probabilities, and major amputation rates were compared between genders and diabetic versus non-diabetic patients.</p><p><strong>Results: </strong>One hundred thirty-four patients and 142 limbs were included. 49% of lesions classified as TASC-II D. Technical success was achieved in 95% of limbs. Median follow-up was 24 months (IQR: 13-36 months). 31% had died by study conclusion. KM-estimated freedom from all-cause mortality was 67% (95% CI: 59-77%) at 48 months. The major amputation rate was 25% (N.=35 limbs). KM-estimated freedom from major amputation was 64% (95% CI: 48-85%) at 46 months. There was no significant difference in major amputation-free survival between genders: females 76% (95% CI 63-91%) vs. males 70% (95% CI 60-82%) at 36 months. The rate of major amputations was higher in patients with diabetes (19/55, 35% vs. 16/87, 18%, P=0.048), however, KM-estimates showed no statistically significant difference over time, P=0.570.</p><p><strong>Conclusions: </strong>In this CLTI cohort unsuitable for vein bypass surgery, 25% underwent major amputation and 31% died following endovascular treatment during a median follow-up of 24 months. Larger comparative studies, including conservative treatment, are needed to define optimal management for complex femoropopliteal lesions.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"115-123"},"PeriodicalIF":1.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147473503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenteric vein thrombosis: a case series and current literature review.","authors":"Ilektra Kyrochristou, Dimitrios Liakopoulos, Georgios Anagnostopoulos, Konstantina Psalla, Georgios Lampropoulos, Athanasios Rogdakis","doi":"10.23736/S0392-9590.25.05399-4","DOIUrl":"10.23736/S0392-9590.25.05399-4","url":null,"abstract":"<p><strong>Background: </strong>Mesenteric vein thrombosis (MVT) is a rare clinical entity that occurs secondary to other diseases in approximately 90% of cases. Early diagnosis and treatment of intestinal hypoperfusion can be lifesaving for the patient. Here, we present a case series of MVT in our department over the past decade, highlighting how they were treated and the need for intervention in cases of intestinal ischemia, as well as the long-term results of newer anticoagulants.</p><p><strong>Methods: </strong>Retrospective study of patients with MVT during the period 2013-2023 who were hospitalized in our department. We present the clinical presentation, the diagnostic process and the therapeutic measures, the follow-up of the patients to this day, and their outcomes.</p><p><strong>Results: </strong>Eleven patients suffering from MVT were admitted to our surgical department during the study, with a mean age of 59.7 years. Three of them had an extension of the thrombus into the portal vein. In total, six patients were taken to the operating room and underwent either thrombolysis (N.=3) or enterectomy (N.=3). The rest were treated conservatively with heparin or warfarin. Mortality was estimated at 18% (2/11), positive thrombophilia screening was found in six patients (66.6%, 6/9), while 4/11 were diagnosed with malignant disease. Three patients voluntarily discontinued their treatment 3 months after the episode; however, despite that, they did not develop a new thrombotic event.</p><p><strong>Conclusions: </strong>Due to its rarity, the management of MVT has not been established with protocols based on thorough research. The initial conservative treatment, and the subsequent decision for surgical intervention, depending on the patient's clinical course, are still the pillars of treatment. In the long term, the newer anticoagulants and a finite course of treatment seem to be non-inferior to traditional treatment options. However, large-scale multicenter studies are needed to confirm the results.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"65-70"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145503767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}